Update your tester profile Login
  • Studies for Particpants Diagnosed with Type 2 Diabetes

    Throughout 2015, Prism will be conducting several studies for participants diagnosed with type 2 diabetes.  These studies will be posted on our website once recuritment is officially underway.  

    Don't see a study listed?  Maybe a study is posted but it's not a match for you?  That's ok, we still want to hear from you!  Each study will have an unique set of qualifications.  Register with our database now so we can identify the right study for you as soon as it becomes availble.

    The information you provide is only used to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1418: Healthy Male and Female Particpants

    Research Purpose: Study 1418 is designed to evaluate an investigational drug being developed for the treatment of influenza. Participants will receive twice daily, oral doses of the investigational drug or a placebo.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug
    • The male reproductive safety of the investigational drug  

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate; males who have a vasectomy cannot participate.

    Females

    Women are allowed to participate

    Age

    18-65 years

    Body Mass Index (BMI)

    Greater than or equal to 16 kg/m²

    Weight

    Greater than or equal to 96.8 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine use in the 3 months prior to the start of the study until study completion of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 2 years before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Prescribed/stable hormonal birth control is allowed

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 weeks (for women) and 15 weeks (for men).

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 1 and a half weeks (11 overnights)

    Outpatient Visits

    • Women: There is one outpatient visit and one follow-up phone call.
    • The outpatient visit will last between approximately 1.5 hours
    • Men: There are 4 outpatient visits.  Each visit will last approcimately 2 hours.

     

    Compensation: Up to $2,975.00 (Women)

                           Up to $3,525.00 (Men)

     

     

     

     

     

     

  • Study 1419: Participants with Type 1 or Type 2 Diabetes

    Research Purpose: Study 1419 is designed to evaluate an investigational injected medication being developed for the treatment of diabetic kidney disease in participants with either type 1 or type 2 diabetes and various degrees of kidney damage. 

    Minimum Screening Qualifications:

    Males

    Males are allowed to participate

    Females

    Females are allowed to participate.

    Age

    • Type 1 Diabetes: Ages 21-80
    • Type 2 Diabetes: Ages 30-80

    Body Mass Index (BMI)

    Less than or equal to 45 kg/m²

    Weight

    No weight requirements

    Tobacco/Nicotine Use

    Tobacco use is prohibited while at clinic.  Use of tobacco at other times is allowed

    Alcohol/Drug Abuse History

    History of drug/alcohol abuse will be considered on a case by case basis.

    Health History

    Excluded:

    • History of or currently requiring dialysis
    • History of kidney or other organ transplantation

    Other exclusions related to health history may apply. Prism staff will review participants’ health history to determine eligibility.

    Medications

    Excluded:

    • Ongoing treatment of systemic immunosuppression therapy

    Other medications exclusions may apply, however; stable use of many medications is allowed.  Prism staff will review participants’ medication lists to determine eligibility.

     

    Study Time Commitment: For participants who qualify based on screening evaluations, study participation will last for approximately 1 year.

    Inpatient Stays

    • There are no overnight stays during this study

    Outpatient Visits

    • Following the two part screen, there are 16 outpatient visits over the course of approximately 54 weeks.
    • Three outpatient visits will last between 3-4 hours.  The remaining 13 outpatient visits will last approximately 45 minutes

     

    Compensation for study participation time: Up to $1,450.00.

     

     

     

    V1 09FEB2015  1419VPI

     

  • Study 1505: Healthy Pregnant Females 18 or Older and Healthy Males and Females Ages 60 and Older

     

     

    Research Purpose: Study 1505 is a non-pharmaceutical clinical trial designed to determine the normal range of thyroid levels in healthy adults.  Blood will be drawn to establish the following:

    • The normal range of thyroid levels in healthy pregnant females
    • The normal range of thyroid levels  in healthy males and females  ages 60 years or older

     

    Minimum Screening Qualifications:

    Males

    Males 60 years  or older are allowed to participate

    Non-Pregnant Females

    Non-pregnant women 60 years or older are allowed to participate

    Pregnant Females

    Pregnant females 18 years or older are allowed to participate

    Body Mass Index (BMI)

    No weight or BMI requirements

    Tobacco/Nicotine Use

    No tobacco use when at research unit.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    Must be generally healthy with no personal or family history of thyroid diseases or conditions.

    Restricted Medications

    No use of prescription medications, aspirin, or Unisom use in the 30 days before the blood draw.

    Allowed Medications

    Use of prenatal vitamins are allowed.  Use of non-prescription medications, vitamins, or supplements not listed here will be considered on a case by case basis.

     

    Study Time Commitment: For qualified participants, this study requires one brief outpatient visit lasting approximately 1 hour. 

     

    Compensation: Up to $50.00

     

     

     

    1505 Beckman AD v2, 24MAR2015

  • Study 1503: Male and Female Participants

    New Study for Healthy Adults age 18 to 65.  Prism is now enrolling volutneers to particpate in Study 1503. Receive up to $2,050.00 for this research study which includes 1 stay of 2 nights with 15 follow-up visits.  Check to see if you qualify and learn more here:

     

    Study 1503: Male and Female Participants

    Study 1503 is a research study designed to evaluate an investigational drug being developed for the treatment of high cholesterol.  Participants will receive a single dose of the investigational drug via injection. 

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Weight

    Must weigh between 132-198 pounds

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 weeks.  The study requires two screening visits prior to study participation.

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 2 days (2 overnights)

    Outpatient Visits

    • There will be 15 outpatient visits
    • The outpatient visits will last approximately 30 minutes with 3 visits lasting up to 60 minutes and the final visit which will last up to 120 minutes.

     

    Compensation: Up to $2,050.00

    The 1st screening period starts of Friday May 15, 2015.  For information regarding this study contact a recrutier at 651-289-2097 or viea email at studyinfo@prismresearchinc.com

     

    Enroll in our database to recieve updates about studies you might qualify for:  http://bit.ly/PrismDatabaseSignUp

     

     

     

    B1481026_Site1001-Internet Ad_v3.0_28Apr2015

Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel